Trigeminal neuralgia is a relatively common condition in clinical practice; however, the trigeminal nerve may also give rise to a neoplastic process known as a trigeminal schwannoma. Trigeminal schwannomas are solitary, slow-growing benign tumors that frequently exhibit cystic change and hemorrhagic necrosis. They are encapsulated and classified as extra-axial tumors. The trigeminal nerve originates from the ventrolateral surface of the brainstem and courses anterosuperolaterally through the cerebellopontine cistern toward the petrous apex. Consequently, trigeminal schwannomas may affect multiple neural structures within the brain and give rise to a wide spectrum of symptoms.

Common Anatomical Sites of Origin

Trigeminal schwannomas most commonly arise at the level of the Gasserian (semilunar) ganglion. Approximately 50% are located extradurally within the middle cranial fossa, grow slowly, and may extend into the cavernous sinus and the superior orbital fissure. A second group arises from the trigeminal nerve root; approximately 30% are located intradurally within the posterior cranial fossa and may involve adjacent cranial nerves. Approximately 25% are located along the anterior margin of the petrous temporal bone and extend across both the middle and posterior cranial fossae, with both intradural and extradural components. Twenty percent are dumbbell-shaped tumors involving both the middle and posterior fossae simultaneously.

Late-Stage Symptoms of Trigeminal Schwannomas

Although trigeminal schwannomas are benign tumors, progressive growth ultimately results in compression of multiple intracranial neural structures and a sustained elevation of intracranial pressure. In the late stages of the disease, patients commonly experience headache of increasing severity over time. Additional manifestations include ipsilateral facial sensory disturbance, typically numbness, though pain and paresthesia may also occur. Other symptoms include unilateral hemifacial spasm, auditory disturbance, focal seizures, hemiparesis, gait abnormality, raised intracranial pressure, Eustachian tube obstruction, otalgia, and exophthalmos. Diplopia, exophthalmos, and visual field deficits may be present, along with parasellar or paratrigeminal syndrome. Cerebellopontine angle syndrome is frequently observed, encompassing hearing loss, dizziness, and gait abnormality.

Can Trigeminal Schwannomas Be Cured?

Professor James T. Rutka — member of the WANG Advisory Board under INC, former President of the World Academy of Neurological Surgery, and Chief of Neurosurgery at the Hospital for Sick Children in Toronto, Canada — has stated that surgical resection is the preferred treatment for trigeminal schwannomas. Every effort should be made to achieve gross total resection; in principle, when complete surgical removal is accomplished, recurrence is generally not expected. However, achieving gross total resection is technically challenging. For larger tumors or those in which the capsule is adherent to surrounding vasculature and cranial nerves, only subtotal resection may be feasible. The greatest extent of resection is most likely to be achieved under the hands of internationally recognized, top-tier neurosurgical specialists.

When a trigeminal schwannoma has reached an advanced stage, extensive surgical resection is often not possible, and the risk of postoperative recurrence is considerably higher. Resectability is related not only to the extent of surgical removal but also to tumor location. Dumbbell-shaped tumors present the greatest surgical challenge; straddling the petrous apex across both the middle and posterior cranial fossae, with extension both intracranially and extracranially, complete intraoperative resection is rarely achievable, and postoperative recurrence rates are correspondingly higher. Postoperative complications include cranial nerve injury, cerebrospinal fluid leak, meningitis, and hydrocephalus. Many patients experience persistent trigeminal nerve dysfunction of varying severity following surgery. Preexisting neurological deficits, however, may show improvement postoperatively. Newly acquired cranial nerve deficits following surgery — such as abducens nerve (CN VI) and oculomotor nerve (CN III) palsies — typically resolve within four months.

INC International Neurosurgery reminds patients: Trigeminal schwannomas can be effectively managed when diagnosed and treated at an early stage. Patients are strongly advised to seek timely evaluation and treatment at a qualified neurosurgical center. Allowing the disease to progress to an advanced stage not only renders treatment far more difficult, but also subjects patients to a considerably greater burden of symptoms.

Reference: https://www.incsg.com/sanchaqiaoliu/251.html